Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To assess the efficacy of apatinib in first, second, third, fourth and fifth lines of treatment to patients with advanced/metastatic Non-Small-Cell-Lung-Cancer.

Next Previous
Search
Trial Profile

To assess the efficacy of apatinib in first, second, third, fourth and fifth lines of treatment to patients with advanced/metastatic Non-Small-Cell-Lung-Cancer.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

Most Recent Events

  • 10 Oct 2018 New trial record
  • 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top